The National Cancer Institute is offering a grant for Research Programs within the Pediatric Preclinical Testing Consortium (PPTC) initiative. This grant focuses on in vivo and in vitro testing of pediatric anticancer drug candidates, aiming to generate reliable data for new agent prioritization decisions. Applicants can propose programs for leukemia, tumors of the central nervous system, other solid tumors, or in vitro testing, with expertise in the specific tumor types required. Collaborative efforts with the PPTC Coordinating Center are essential. Applications are due by November 13, 2014, to contribute to the development of a rigorous preclinical testing system for pediatric anticancer drug candidates.
Opportunity ID: 264192
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-14-018 |
| Funding Opportunity Title: | Pediatric Preclinical Testing Consortium: Research Programs (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Sep 05, 2014 |
| Last Updated Date: | Sep 05, 2014 |
| Original Closing Date for Applications: | Nov 13, 2014 |
| Current Closing Date for Applications: | Nov 13, 2014 |
| Archive Date: | Dec 14, 2014 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities County governments Private institutions of higher education Independent school districts State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Small businesses Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) is for Research Programs for in vivo and in vitro testing of the activity of pediatric anticancer drug candidates. These Research Programs are the fundamental part of the Pediatric Preclinical Testing Consortium (PPTC) initiative, which also includes a PPTC Coordinating Center (supported under RFA-CA-14-019). The main goal for PPTC is to develop a rigorous preclinical testing system for pediatric anticancer drug candidates and to generate reliable data that can be used to inform new agent prioritization decisions. This FOA invites applications for drug testing Research Programs focused on specific tumor types that are particularly relevant to pediatric oncology. Each application must propose only one testing Research Program from the following four types:Type A: Research Program for leukemia in vivo testing;Type B: Research Program for tumors of central nervous system (CNS) in vivo testing; Type C: Research Program for other (non-CNS) solid tumors testing in vivo; and Type D: Research Program for in vitro testing.Applicants may propose Research Programs of more than one type but only through separate applications for each. Applicants proposing in vivo testing programs must be capable of quantitative assessment of tumor regression and time to event for 6 to 10 new agents (or combinations of agents) annually across relevant, well-characterized preclinical models. All applicants are expected to have substantial expertise regarding the biology and therapeutic opportunities for the tumor types that they propose to study. The PPTC Research Program Awardees will be required to collaborate closely with the PPTC Coordinating Center. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14-018.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Corrected Eligible Applicants field | Sep 05, 2014 | |
| Sep 05, 2014 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-14-018 |
| Funding Opportunity Title: | Pediatric Preclinical Testing Consortium: Research Programs (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Sep 05, 2014 |
| Last Updated Date: | Sep 05, 2014 |
| Original Closing Date for Applications: | Nov 13, 2014 |
| Current Closing Date for Applications: | Nov 13, 2014 |
| Archive Date: | Dec 14, 2014 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities County governments Private institutions of higher education Independent school districts State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Small businesses Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) is for Research Programs for in vivo and in vitro testing of the activity of pediatric anticancer drug candidates. These Research Programs are the fundamental part of the Pediatric Preclinical Testing Consortium (PPTC) initiative, which also includes a PPTC Coordinating Center (supported under RFA-CA-14-019). The main goal for PPTC is to develop a rigorous preclinical testing system for pediatric anticancer drug candidates and to generate reliable data that can be used to inform new agent prioritization decisions. This FOA invites applications for drug testing Research Programs focused on specific tumor types that are particularly relevant to pediatric oncology. Each application must propose only one testing Research Program from the following four types:Type A: Research Program for leukemia in vivo testing;Type B: Research Program for tumors of central nervous system (CNS) in vivo testing; Type C: Research Program for other (non-CNS) solid tumors testing in vivo; and Type D: Research Program for in vitro testing.Applicants may propose Research Programs of more than one type but only through separate applications for each. Applicants proposing in vivo testing programs must be capable of quantitative assessment of tumor regression and time to event for 6 to 10 new agents (or combinations of agents) annually across relevant, well-characterized preclinical models. All applicants are expected to have substantial expertise regarding the biology and therapeutic opportunities for the tumor types that they propose to study. The PPTC Research Program Awardees will be required to collaborate closely with the PPTC Coordinating Center. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14-018.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-14-018 |
| Funding Opportunity Title: | Pediatric Preclinical Testing Consortium: Research Programs (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 05, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Nov 13, 2014 |
| Archive Date: | Dec 14, 2014 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Small businesses For profit organizations other than small businesses Public housing authorities/Indian housing authorities Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) is for Research Programs for in vivo and in vitro testing of the activity of pediatric anticancer drug candidates. These Research Programs are the fundamental part of the Pediatric Preclinical Testing Consortium (PPTC) initiative, which also includes a PPTC Coordinating Center (supported under RFA-CA-14-019). The main goal for PPTC is to develop a rigorous preclinical testing system for pediatric anticancer drug candidates and to generate reliable data that can be used to inform new agent prioritization decisions.
This FOA invites applications for drug testing Research Programs focused on specific tumor types that are particularly relevant to pediatric oncology. Each application must propose only one testing Research Program from the following four types: Type A: Research Program for leukemia in vivo testing; Applicants may propose Research Programs of more than one type but only through separate applications for each. Applicants proposing in vivo testing programs must be capable of quantitative assessment of tumor regression and time to event for 6 to 10 new agents (or combinations of agents) annually across relevant, well-characterized preclinical models. All applicants are expected to have substantial expertise regarding the biology and therapeutic opportunities for the tumor types that they propose to study. The PPTC Research Program Awardees will be required to collaborate closely with the PPTC Coordinating Center. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14-018.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-C | FORMS-C | PKG00205224 | Oct 13, 2014 | Nov 13, 2014 | View |
Package 1
Mandatory forms
264192 RR_SF424_2_0-2.0.pdf
264192 PHS398_ResearchPlan_2_0-2.0.pdf
264192 PHS398_CoverPageSupplement_2_0-2.0.pdf
264192 RR_KeyPersonExpanded_2_0-2.0.pdf
264192 RR_OtherProjectInfo_1_3-1.3.pdf
264192 PerformanceSite_2_0-2.0.pdf
Optional forms
264192 RR_SubawardBudget30_1_3-1.3.pdf
264192 PlannedReport-1.0.pdf
264192 PHS398_CumulativeInclusionReport-1.0.pdf
264192 PHS398_ModularBudget_1_2-1.2.pdf
264192 RR_Budget_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
